Wastewater Surveillance Campaign for Boosting Vaccinations

Age: Any Age

Sex: Any

Trial Phase: Academic

Sponsor: Syracuse University

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Compensation: Varies

Number of Visits: Unknown

100000 Participants Needed

Trial Summary

Do I need to stop my current medications for this trial?

The trial does not involve direct interaction with participants, so you won't need to stop taking your current medications.

What data supports the effectiveness of the treatment Wastewater vaccine prompts?

The effectiveness of community-wide outreach campaigns in increasing vaccination rates is supported by a study showing a 94% increase in pneumococcal vaccinations in a targeted area, suggesting that similar strategies could boost vaccination rates when applied to wastewater vaccine prompts. ^{1 2 3 4 5}

How does the Wastewater Surveillance Campaign for Boosting Vaccinations differ from other treatments?

This treatment is unique because it uses wastewater surveillance to monitor community virus levels, which can help identify areas with low vaccination rates and target them for vaccination campaigns. Unlike traditional methods that rely on clinical testing, this approach can detect virus presence in communities even when clinical data is insufficient, allowing for a more inclusive and rapid public health response. ^{6 7 8 9 10}

What is the purpose of this trial?

The goal of the study is to determine the effect of a communications campaign sharing wastewater surveillance data to influence vaccine uptake in a metropolitan and non-metropolitan environment. The study will be conducted in Onondaga and Cayuga counties in New York State. Individuals of all ages within the selected counties, located in metropolitan and non-metropolitan environments will receive the intervention. The evaluation study design is a comparison-control trial. The primary outcome measure is the proportion of vaccine-eligible individuals in the county that received the COVID-19 vaccine stratified by type of vaccine dosage and age group. Vaccination data will be aggregated to the county by the State Department of Health and shared with the research team. Wastewater data will be pulled from the wastewater surveillance network. A difference in differences analysis will be used to estimate the effect of the intervention on both the outcomes between intervention and comparison groups following the intervention, while adjusting for potential confounding factors.

Eligibility Criteria

This trial is for all age groups in Onondaga and Cayuga counties, NY. It's a public health study with no direct interaction with participants; instead, it focuses on county-level vaccine uptake based on wastewater data.

Inclusion Criteria

None - county-level vaccine uptake - no direct interaction with people getting vaccines

You do not come into contact with individuals receiving vaccinations.

You have received the vaccine at a county-level.

Exclusion Criteria

None

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Intervention

Participants receive communications on the level of SARS-CoV-2 as identified in the wastewater

3 months

Follow-up

Participants are monitored for vaccine uptake after the intervention

4 weeks

Treatment Details

Interventions

• Wastewater vaccine prompts

Trial Overview The study tests if sharing local COVID-19 wastewater surveillance data can encourage more people to get vaccinated. It compares the change in vaccination rates before and after this information campaign between different areas.

Participant Groups

Group I: Intervention arm Experimental Treatment 1 Intervention

Receives communications on level of SARS-CoV-2 as identified in the wastewater

Group II: Comparison arm Active Control 1 Intervention

Who Is Running the Clinical Trial?

Syracuse University

Lead Sponsor

Trials

54

Recruited

118,000+

References

1. United States pubmed.ncbi.nlm.nih.gov

Operationalizing influenza vaccination in an urban safety-net emergency department. [2022]

2. United States pubmed.ncbi.nlm.nih.gov

Emergency department immunization of the elderly with pneumococcal and influenza vaccines. [2019]

3. Netherlands pubmed.ncbi.nlm.nih.gov

Pneumococcal immunizations at flu clinics: the impact of community-wide outreach. [2019]

4. United States pubmed.ncbi.nlm.nih.gov

An emergency department-based pneumococcal vaccination program could save money and lives. [2019]

5. England pubmed.ncbi.nlm.nih.gov

Vaccination against 2009 pandemic H1N1 in a population dynamical model of Vancouver, Canada: timing is everything. [2021]

6. Switzerland pubmed.ncbi.nlm.nih.gov

Expanding the Pathogen Panel in Wastewater Epidemiology to Influenza and Norovirus. [2023]

7. United States pubmed.ncbi.nlm.nih.gov

Wastewater Surveillance Data as a Complement to Emergency Department Visit Data for Tracking Incidence of Influenza A and Respiratory Syncytial Virus - Wisconsin, August 2022-March 2023. [2023]

8. United States pubmed.ncbi.nlm.nih.gov

Beyond COVID-19: Designing Inclusive Public Health Surveillance by Including Wastewater Monitoring. [2023]

9. United States pubmed.ncbi.nlm.nih.gov

Using Wastewater Surveillance Data to Support the COVID-19 Response - United States, 2020-2021. [2022]

10. United States pubmed.ncbi.nlm.nih.gov

Wastewater Surveillance for Infectious Disease: A Systematic Review. [2023]